share_log

AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES PROFITABILITY

AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES PROFITABILITY

AVRICORE HEALTH 公司更新——公司已實現盈利。
GlobeNewswire ·  06/03 20:00

VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "Avricore") reports on results for the first three months of 2024, the first period of net profitability for the Company. The Company realized a comprehensive income of $168,537 for the three months ended March 31, 2024 (2023 - loss $191,512) and a net increase in cash of $307,470, demonstrating the Company's commitment to growth while managing operational efficiencies.

溫哥華,不列顛哥倫比亞省,2024年6月3日(環球新聞社)——AVRICORE HEALTH INC.(TSXV: AVCR)(以下簡稱“公司”或“Avricore”)報告了2024年頭三個月的業績,這是公司首次實現淨利潤。公司在截至2024年3月31日的三個月內實現了綜合收入爲168,537美元(2023年虧損191,512美元),現金淨增加307,470美元,展示了公司在管理運營效率的同時致力於增長的承諾。

"HealthTab's end-to-end offering is making the typically complex point-of-care programs in pharmacy easy," said Hector Bremner, CEO of Avricore. "With chronic disease prescribing already coming to some Canadian provinces in early 2025, we're excited to help more pharmacists deliver timely care to patients who need it."

“HealthTab的端到端服務使通常繁瑣的藥房醫療計劃變得更加簡單,”Avricore的CEO Hector Bremner表示。“隨着慢性病處方已經在2025年初涵蓋加拿大的一些省份,我們很高興能夠幫助更多藥劑師爲有需要的病人提供及時護理。”

First quarter 2024 profitable

2024年第一季度盈利

The Company incurred a comprehensive income of $168,537 for the three months ended March 31, 2024 (2023 - loss $191,512) and a net increase in cash of $307,470. In the period ended March 31, 2024 revenue increased by 79% year over year to $1,124,307 and gross profit increased by 130% to $484,791. Gross margin for the period was 43% (2023- 33%) outperforming the Company's target margin of 30%.

公司在截至2024年3月31日的三個月內實現了綜合收入爲168,537美元(2023年虧損191,512美元),現金淨增加307,470美元。在2024年3月31日結束的期間內,營業收入同比增長79%,達到1,124,307美元,毛利潤同比增長130%,達到484,791美元。該期毛利率爲43%(2023年爲33%),超出公司30%的目標毛利率。

3 mo ended March 31
2024 2023
Revenue $1,124,307 $629,241
% Change - year over year 79%
Gross profit $484,791 $210,681
% Change - year over year 130%
Comprehensive Income $168,537 $(191,512)
截至3月31日的3個月
2024 2023
營業收入 $1,124,307 $629,241
同比變化-年增長率 79%
毛利潤 $484,791 $210,681
同比變化-年增長率 130%
綜合收益 $168,537 $(191,512)

The following table highlights selected financial data for each of the eight most recent quarters.

以下表格突出了最近八個季度的選定財務數據。

Quarter Ended Mar
2024
Dec
2023
Sep
2023
Jun
2023
Mar
2023
Dec
2022
Sep
2022
Jun
2022
$ $ $ $
Revenue 1,124,307 1,354,403 953,454 548,049 629,241 997,235 572,228 176,175
Gross profit (loss) 484,791 501,466 261,778 229,471 210,681 168,845 215,961 56,874
Comprehensive income (loss) 168,537 59,584 (285,062) (284,225) (191,512) (244,789) (180,398) (207,363)
Total Assets 2,798,058 2,538,205 2,453,136 2,143,810 2,296,565 2,568,983 2,128,017 1,985,085
季度結束 三月
2024
十二月
2023
9月
2023
六月
2023
三月
2023
十二月
2022
九月
2022
六月
2022
$ $ $ $
營業收入 1,124,307 1,354,403 953,454 548,049 629,241 997,235 572,228 176,175
毛利潤(虧損) 484,791 501,466 261,778 229,471 210,681 168,845 215,961 56,874
綜合收益(損失) 168,537 59,584 (285,062) (284,225) (191,512) (244,789) (180,398) (207,363)
總資產 2,798,058 2,538,205 2,453,136 2,143,810 2,296,565 2,568,983 2,128,017 1,985,085

Looking Ahead

展望未來

The Company is actively pursuing various methods of expansion, both within its home market of Canada and internationally. Some of these opportunities include:

公司正在積極尋求在其加拿大本土市場和國際市場擴張的各種方法。其中一些機會包括:

  • Expanding with Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOURNEXT GEN and CONTOURNEXT ONE, with HealthTab and bringing near-to-patient data into HealthTab results.
  • 與全球糖尿病護理公司Ascensia Diabetes Care合作,在HealthTab中整合他們的血糖監測(BGM)系統,推廣爲CONTOURNEXT GEN和CONTOURNEXT ONE,並將近病人數據引入HealthTab結果。
  • Launching with Rexall Pharmacies, one of Canada's largest and most respected pharmacy brands, the second national chain to roll out HealthTab.
  • 與加拿大最大和最受尊重的藥房品牌之一的Rexall Pharmacies合作推出HealthTab,這是第二個全國連鎖藥房。

The Company continues many other interesting and potentially exciting conversations as it seeks to drive greater collaboration between various parties interested in patient health, both within Canada and internationally.

公司繼續與其他各方展開許多有趣且潛在興奮的對話,旨在促進對患者健康感興趣的各方之間的更大協作,無論在加拿大還是國際上。


Company Objectives
Further expansion of HealthTab with current partners.
Update: There are 777 participating Shoppers Drug Mart pharmacies and Loblaw family stores offering screening tests to patients via HealthTab.

Expansion ofHealthTabin other pharmacy groups in Canada.
Update: The Company is deploying an initial tranche of Rexall Pharmacies and is working towards adding more pharmacy brands to the network.

International expansion.
Update: The Company is expecting to see growth of the UK program and other international markets, which are currently under discussions.

Hiring key positions to support technical and business development efforts.
Update: The team expects to grow in the near future and plans are under consideration.
Revenue growth and profitability.
Update: Achieved profitability inthe first quarter of 2024, a significant milestone

公司目標
與當前合作伙伴進一步擴大HealthTab。
更新:有777家Shoppers Drug Mart藥店和Loblaw家庭商店參與,通過HealthTab向患者提供篩查測試。

在加拿大其他藥房集團中擴大HealthTab。
更新:公司正在向Rexall Pharmacies部署首個額度,並努力增加更多的藥房品牌到網絡中。

國際擴張。
更新:公司預計將會在英國計劃和其他目前正在討論中的國際市場上實現增長。

招聘關鍵職位以支持技術和業務發展工作。
更新:團隊預計在不久的將來會增長,計劃正在考慮中。
營業收入創業板和盈利能力。
更新:2024年第一季度實現盈利,是一個重要的里程碑。HealthTab市場快訊

HealthTab Market Fast Facts

臨床檢測市場將在2030年達到932.1億美元(數據來源)。

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
  • There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
  • 預計到2030年將有將近1360萬加拿大人患糖尿病或糖尿病前期,其中許多人沒有被診斷出來(數據來源)。
  • 超過三分之一的美國人,約8800萬人,有糖尿病前期(數據來源)。
  • 每年有近16萬名20歲及以上的加拿大人被診斷爲患有心臟病,往往在心臟病發作後才被診斷出來(數據來源)。
  • 加拿大有超過10,000家藥房,在美國有88,000家藥房,英國有將近12,000家藥房。
  • 關於HealthTab

About HealthTab

HealthTab是一個全方位的診所檢測解決方案,將最佳的診所技術與安全的基於雲的平台相結合,解決全球衛生問題。系統只需從手指上取幾滴血液,即可當場生成實驗室準確的結果,並實時彙報數據。檢測菜單包括多達23種重要生物標誌物,用於篩查和管理慢性疾病,如糖尿病和心臟病(例如,HbA1c,脂質譜,eGFR)。HealthTab還新增了細菌和病毒測試功能,例如鏈球菌和COVID-19。

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

HealthTab網絡模型與任何一種藥店模型都不同。它賦予權威、值得信賴的藥劑師在初級醫療保健中扮演更重要的角色,同時使患者更加掌控自己的健康。它還降低了成本和等待時間,並提供了許多潛在的收入來源,包括設備租賃和耗材、直接獲取測試、疾病預防和管理計劃、贊助的健康計劃、去中心化的臨床試驗、現實世界數據(RWD)集以及API通過第三方應用程序集成。

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

關於Avricore Health Inc.

About Avricore Health Inc.

Avricore Health Inc.(tsxv:avcr)是一家專注於收購和開發早期技術以推進藥店實踐和患者護理的藥店服務創新者。通過其旗艦產品HealthTab,該公司的全資子公司,其使命是通過在社區藥店創建全球最大的快速測試設備網絡,使可操作的健康信息更加普遍。

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc.(tsxv:avcr)是一家專注於收購和開發早期技術以推進藥店實踐和患者護理的藥店服務創新者。通過其旗艦產品HealthTab,該公司的全資子公司,其使命是通過在社區藥店創建全球最大的快速測試設備網絡,使可操作的健康信息更加普遍。

Contact:

聯繫方式:

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com

Avricore Health Inc.
何塞·布萊納,首席執行官604-773-8943
info@avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

關於前瞻性聲明的警示
本新聞稿中所涉及的Avricore Health的期望、計劃、意圖或策略涉及未來的前瞻性聲明,這些前瞻性聲明不是事實,涉及一系列風險和不確定性。Avricore Health通常使用“展望”、“將”、“可能”、“將會”、“可能”、“保持”、“計劃”、“相信”、“可能”、“預計”、“打算”、“預期”、“估計”、“未來”、“定位”、“潛力”、“項目”、“仍有”、“安排”、“受”、“即將”等表達方式來幫助識別前瞻性聲明。在本新聞稿中,前瞻性聲明包括關於:完成配售的完成以及預期的時間以及公司對配售所得款項的預期用途;HealthTab平台向藥劑師和患者提供的獨特功能。前瞻性聲明反映Avricore Health管理層當時的期望、信念、假設、估計和預測。在本新聞稿中的前瞻性聲明基於Avricore Health在本新聞稿發佈之日可獲得的信息。相信前瞻性聲明在製作時是正確的,但最終可能證明是不正確的。這些聲明並不是Avricore Health未來業績的保證,並受到一些風險、不確定性和其他因素的影響,其中一些因素超出其控制範圍,並可能導致實際結果與當前預期有所不同,包括但不限於:未能滿足監管要求;市場變化;經濟狀況可能出現下滑;以及Avricore的公共文件中描述的其他風險因素。這些前瞻性聲明僅在發佈之日起生效,除非法律要求否則不對其進行公開更新以反映新信息或未來事件或情況的發生。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

tsxv的監管服務提供商(在其政策中定義該術語)對本公告的充分性或準確性不承擔責任。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論